Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Completed · Phase 2
Conditions studied: Melanoma
In brief
The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles.
Key facts
- Study ID
- NCT02014441
- Run by
- Amgen
- People needed
- 61
- Starts
- 2014-04-07
- Expected to finish
- 2018-04-19
- Last updated by the study team
- 2019-11-20
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Tampa, Florida, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Louisville, Kentucky, United States
- Research Site — Fridley, Minnesota, United States
- Research Site — Minneapolis, Minnesota, United States
- Research Site — New Brunswick, New Jersey, United States
- Research Site — Albuquerque, New Mexico, United States
- Research Site — Winston-Salem, North Carolina, United States
- Research Site — Germantown, Tennessee, United States
- Research Site — Dallas, Texas, United States
- Research Site — Salt Lake City, Utah, United States
- Research Site — Calgary, Alberta, Canada
- Research Site — Edmonton, Alberta, Canada
- Research Site — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.